Get the Stockscreener App
21.62
4.22%
0.875
Pre-market:
21.66
0.035
+0.16%
Catalyst Pharmaceuticals Inc stock is traded at $21.62, with a volume of 1.48M.
It is up +4.22% in the last 24 hours and down -16.31% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$20.75
Open:
$21.01
24h Volume:
1.48M
Relative Volume:
1.18
Market Cap:
$3.21B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
18.33
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+0.82%
1M Performance:
-16.31%
6M Performance:
-5.15%
1Y Performance:
+38.53%
1-Day Range:
$20.96
$21.66
1-Week Range:
$20.62
$21.66
52-Week Range:
$15.26
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.62 | 3.21B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.96 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.19 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.69 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Stanley Laman Group Ltd. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 5.2% Following Insider Selling - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $42,272.00 in Stock - MarketBeat
Trading (CPRX) With Integrated Risk Controls - news.stocktradersdaily.com
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Nasdaq
Wesbanco Bank Inc. Invests $461,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Insider Sell: Preethi Sundaram Sells Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus
Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC - MarketBeat
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Nasdaq
Insider Sell: Patrick Mcenany Sells 200,000 Shares of Catalyst P - GuruFocus
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now - MSN
Catalyst Pharmaceuticals (CPRX) CEO Acquires 70,000 Shares | CPR - GuruFocus
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Insider Sell: Richard Daly Sells 70,000 Shares of Catalyst Pharm - GuruFocus
Catalyst Pharmaceuticals (CPRX) CEO Acquires 70,000 Shares | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Appoints Dr. William Andrews As New Chief Medical Officer - Yahoo Finance
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com South Africa
Catalyst Pharma Appoints New Chief Medical Officer - TipRanks
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Catalyst Pharmaceuticals names new Chief Medical Officer - Investing.com
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Names New Chief Medical Officer | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Announces Appointment of William T. And - GuruFocus
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CPRX Stock News - GuruFocus
Catalyst Pharmaceuticals Taps Harvard-Yale Veteran with 18 Years Rare Disease Expertise as New CMO - Stock Titan
What is Zacks Research’s Forecast for CPRX FY2025 Earnings? - Defense World
(CPRX) Trading Report - news.stocktradersdaily.com
Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Zacks Research Brokers Raise Earnings Estimates for CPRX - Defense World
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors - simplywall.st
ProShare Advisors LLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
D. E. Shaw & Co. Inc. Buys Shares of 18,173 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Decreased by Jane Street Group LLC - Defense World
Cetera Investment Advisers Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Ameriprise Financial Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Transcript : Catalyst Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com
Catalyst Pharmaceuticals at Bank of America 2025: Strategic Expansion and Growth - Investing.com Canada
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
The Strong Earnings Posted By Catalyst Pharmaceuticals (NASDAQ:CPRX) Are A Good Indication Of The Strength Of The Business - Yahoo Finance
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sundaram Preethi | Chief Strategy Officer |
Jun 11 '25 |
Sale |
26.42 |
1,600 |
42,272 |
41,081 |
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):